MetaVia Inc. (MTVA) stock
Close on Nov 11, 2026Market cap $9.49MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $9.49M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 1.39
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$14.45M
- EPS, diluted
- -$7.35
- Free cash flow
- -$15.70M
- Book value per share
- $1.15
- Diluted shares
- 6M
Trading
- Next earnings
- Q3 FY2026, expected soon
- Previous close
- $1.49
- Open
- $1.48
- Day's range
- $1.40 – $1.61
- Volume
- 129,438
- Average volume (20 days)
- 192,626
- Beta (5 years)
- 0.49
- 52-week range
- $0.97 – $13.42
- RSI (14 days)
- 53.0
- Volatility (1 year)
- 153.8%
- Relative volume
- 0.61×
- WACC
- 7.4%
Market cap history
Month-end market cap since 2016, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | MTVA | S&P 500 | Difference | MTVA per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +2.1% | -2.4% | +4.5 pts | ||
| 3 months | +1.4% | -1.2% | +2.6 pts | ||
| Year to date | -82.9% | +12.3% | −95.2 pts | ||
| 1 year | -82.9% | +12.4% | −95.4 pts | ||
| 3 years | -96.2% | +78.8% | −175.0 pts | -66.4% | +21.4% |
| 5 years | -100.0% | +75.2% | −175.1 pts | -80.2% | +11.9% |
| 10 years | -100.0% | +311.1% | −411.1 pts | -72.6% | +15.2% |
Thirteen years at a glance
Fiscal years 2013 to 2025 and trailing twelve months, USD
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases MetaVia filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Update
- Update
- Update
- Update
- Update
About MetaVia
Pharmaceutical Preparations
The company is a clinical-stage biotechnology business primarily focused on researching and developing novel pharmaceuticals to treat cardiometabolic diseases. Its core clinical pipeline comprises two main drug candidates: vanoglipel (DA-1241), an orally administered GPR119 agonist being evaluated for metabolic dysfunction-associated steatohepatitis and type 2 diabetes mellitus, and DA-1726, an oxyntomodulin analog targeting the glucagon-like peptide-1 receptor and glucagon receptor for the treatment of obesity. The business also maintains four legacy programs spanning viral, neurodegenerative, and cardiometabolic indications, which it considers for out-licensing and divestiture opportunities, including an out-licensed candidate for painful diabetic neuropathy. Its primary end customers are prospective patients suffering from cardiometabolic disorders.
Company profile, executives and historyMetaVia stock: common questions
What is MetaVia's stock price?
MTVA closed at $1.44 on Nov 11, 2026, down 3.36% on the day. Over the past 52 weeks it traded between $0.97 and $13.42.
What is MetaVia's market cap?
MetaVia was worth $9.49M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is MTVA's P/E ratio?
MetaVia lost money over fiscal 2025 (diluted EPS -$7.35), so it has no meaningful P/E ratio.
Does MetaVia pay a dividend?
No. MetaVia has not paid a cash dividend over the last twelve months.
When does MetaVia report earnings next?
MetaVia's Q3 FY2026 results are due soon; the company has not yet filed them with the SEC.
How has MTVA stock performed over the past year?
Including dividends, MTVA returned -82.9% over the past year, against +12.4% for the S&P 500.
Who are MetaVia's competitors?
Companies most similar to MetaVia by business, industry and size include BMEA, VTVT, GPCR, SKYE, SEPN.
See a number that looks wrong?